Myelodysplastic Syndrome: Epidemiology Forecast to 2028

Myelodysplastic Syndrome: Epidemiology Forecast to 2028

  • May 2020 •
  • 40 pages •
  • Report ID: 5909063 •
  • Format: PDF
Myelodysplastic Syndrome: Epidemiology Forecast to 2028

MDS are rare and a diverse group of clonal hematopoietic malignancies characterized by cytogenetic and molecular abnormalities, causing bone marrow failure and risk of progression to AML.MDS can affect people of any age but usually is most common in the 70 years and older population, with approximately 86% of newly diagnosed cases in older population over the age of 60 years.

MDS patients present with symptoms related to peripheral cytopenias, though they may also be asymptomatic and routine laboratory findings might not detect anything significant except abnormal blood counts.

Epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and MDS incidence and prevalence. Epidemiologists applied country-specific incidence and prevalence rates of MDS, wherever available, to each country’s population to obtain the number of estimated diagnosed incident and prevalent cases.

The following data describes epidemiology of MDS cases.In 2018, the 8MM had 90,332 diagnosed incident cases of MDS.

This is expected to increase to 111,861 diagnosed incident cases by 2028, at an Annual Growth Rate (AGR) of 2.38%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. The 8MM will also see an increase in five-year diagnosed prevalent cases of MDS throughout the forecast period at an AGR of 2.35%, with 236,076 cases in 2018 and 291,581 in 2028. The development of more effective therapies, particularly for elderly patients, would improve survival from MDS.

- Myelodysplastic syndrome (MDS) Epidemiology Report provides an overview of the risk factors and global trends of MDS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
- This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8MM: diagnosed incident cases and five-year diagnosed prevalent cases of MDS, and diagnosed incident cases of MDS/myeloproliferative neoplasms (MDS/MPN); diagnosed incident cases of MDS by subtypes (MDS with single lineage dysplasia, MDS with ring sideroblasts, MDS with multilineage dysplasia, MDS excess blasts, MDS with isolated del(5q), and MDS, unclassifiable), risk groups (very low risk, low risk, intermediate risk, high risk, and very high risk), primary/secondary, and mutations (IDH1, IDH2, SF3B1, ASXL1, TET2, RUNX1, JAK2, and TP53).
- The MDS Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy
The MDS Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MDS market.
- Quantify patient populations in the global MDS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the cancer subtypes that present the best opportunities for MDS therapeutics in each of the markets covered.
- Understand magnitude of MDS market by biomarkers, risk group, and mutations.

We are very sorry, but an error occurred.
Please contact if the problem remains.